Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allopurinol/verinurad - Astrazeneca

Next Previous
X
Search
Drug Profile

Allopurinol/verinurad - Astrazeneca

Alternative Names: Verinurad/allopurinol - AstraZeneca

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Naphthalenes; Propionic acids; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrimidinones; Small molecules; Uricosurics; Urologics
  • Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Renal failure

Most Recent Events

  • 28 May 2024 No recent reports of development identified for phase-I development in Renal-failure in Germany (PO, Capsule)
  • 15 Jul 2021 AstraZeneca completes a phase I bioavailability trial in Renal failure (In volunteers) in Germany (PO, Capsule) (NCT04550234)
  • 15 Sep 2020 AstraZeneca plans a phase I trial in Renal failure (In volunteers) in Germany in October 2020 (NCT04550234)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top